Hypera SA - Company Profile
Powered by 
All the sales intelligence you need on Hypera SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hypera SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hypera SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hypera SA (Hypera) is a prominent pharmaceutical company that focuses on the development, production, and marketing of a wide range of pharmaceutical products. The company's main activities include the manufacturing of over-the-counter medicines, prescription drugs, and food supplements. Its products include analgesics, flu relief medications, vitamins and supplements; sweeteners, tablets for heartburn and poor digestion. Hypera Pharma's products cater to a diverse customer base, including individuals seeking health and wellness solutions across various segments. Its brands include Benegrip, Coristina D, Engov, Neosaldina and others. The company markets its products online and through a network of distributors and wholesale stores in Brazil. Hypera is headquartered in Sao Paulo, Brazil.
Headquarters
Brazil
Address
Rua Nova Cidade, 404, Vila Olimpia, Sao Paulo, 04.547-070
Website
www.hypera.com.br
Telephone
55 11 36274206
No of Employees
9,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HYPE3 (SAO)
Revenue (2024)
$1.4B
3.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-10.9%
(2024 vs 2023)
Market Cap*
$2.8B
Net Profit Margin (2024)
XYZ
-13.8%
(2024 vs 2023)
* As of and is in US$
Hypera SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Food Supplements | Predsim |
| By Prescription Prpducts | Celestamine |
| Prescription Exempt | Maxtest |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Stake Sale | In July, the company sold its additional stake in Hypera Pharma. |
| 2024 | Contracts/Agreements | In November, the company partnered with eureciclo to offset 122% of its packaging waste, aiming for zero environmental impact. |
| 2022 | Acquisitions/Mergers/Takeovers | In March, the company acquired Sanofi brands in Brazil. |
Competitor Comparison
| Key Parameters | Hypera SA | Eurofarma Laboratorios SA | Ache Laboratorios Farmaceuticos SA | Laboratorio Teuto Brasileiro SA | EMS SA |
|---|---|---|---|---|---|
| Headquarters | Brazil | Brazil | Brazil | Brazil | Brazil |
| City | Sao Paulo | Sao Paulo | Guarulhos | Anapolis | Hortolandia |
| State/Province | - | Sao Paulo | Sao Paulo | Goias | Sao Paulo |
| No. of Employees | 9,000 | 13,000 | 6,000 | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alvaro Stainfeld Link | Chairman | Executive Board | 2025 | 56 |
| Breno Toledo Pires de Oliveira | Chief Executive Officer | Senior Management | 2018 | 51 |
| Ramon Sanches Frutuoso Silva | Chief Financial Officer | Senior Management | 2022 | 39 |
| Mauro Gentile Rodrigues da Cunha | Director | Non Executive Board | 2025 | 55 |
| Luciana Cavalheiro Fleischner Alves de Queiroz | Director | Non Executive Board | 2025 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer